Evidence map›Paper›PMID 36384366›Full record

ArticleEpigenetics2023

Sprouty4 is epigenetically upregulated in human colorectal cancer.

Alexei J Stuckel, Shuai Zeng, Zhen Lyu, Wei Zhang, Xu Zhang, Urszula Dougherty, Reba Mustafi, Tripti Khare, Qiong Zhang, Trupti Joshi and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epigenetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Role of SPRY4 in health and disease.Frontiers in oncology · 2024
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Alexei J StuckelDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Missouri, Columbia, Missouri, 65212, USA.
Shuai ZengBond Life Sciences Center, University of Missouri, Columbia, Missouri, 65201, USA.
Zhen LyuBond Life Sciences Center, University of Missouri, Columbia, Missouri, 65201, USA.
Wei ZhangDepartment of Preventive Medicine and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, 60611, USA.
Xu ZhangDepartment of Medicine, University of Illinois, Chicago, Illinois, 60607, USA.
Urszula DoughertyDepartment of Medicine, Section of Gastroenterology, Hepatology and Nutrition; the University of Chicago, Chicago, Illinois, 60637, USA.
Reba MustafiDepartment of Medicine, Section of Gastroenterology, Hepatology and Nutrition; the University of Chicago, Chicago, Illinois, 60637, USA.
Tripti KhareDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Missouri, Columbia, Missouri, 65212, USA.
Qiong ZhangDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Missouri, Columbia, Missouri, 65212, USA.
Trupti JoshiBond Life Sciences Center, University of Missouri, Columbia, Missouri, 65201, USA.
Marc BissonnetteDepartment of Medicine, Section of Gastroenterology, Hepatology and Nutrition; the University of Chicago, Chicago, Illinois, 60637, USA.
Sharad KhareDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Missouri, Columbia, Missouri, 65212, USA.
University of Missouri · USUniversity of Chicago · USHarry S. Truman Memorial Veterans' Hospital · USNorthwestern University · USUniversity of Illinois Chicago · US

Funding

CXCR4 as a target for colon cancer chemopreventionR01CA240710 · NCI · UNIVERSITY OF CHICAGO · PI BISSONNETTE, BRUCE MARC · 2019 to 2023
$1.8M
Deciphering the role of Sprouty2 in CRC progression, treatment and recurrenceR03CA249487 · NCI · UNIVERSITY OF MISSOURI-COLUMBIA · PI KHARE, SHARAD · 2020 to 2020
$146k
BLRD VA I01 BX000824NCI NIH HHS R01 CA240710NCI NIH HHS R03 CA249487
6 · The paper itself

Abstract

Sprouty4 (SPRY4) has been frequently reported as a tumor suppressor and is therefore downregulated in various cancers. For the first time, we report that SPRY4 is epigenetically upregulated in colorectal cancer (CRC). In this study, we explored DNA methylation and hydroxymethylation levels of

Indexed as

Colorectal NeoplasmsDNA MethylationCell Line, TumorGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansIntracellular Signaling Peptides and ProteinsNerve Tissue ProteinsRNA, MessengerIntracellular Signaling Peptides and ProteinsNerve Tissue ProteinsRNA, MessengerSPRY4 protein, humanColorectal cancerDNA hydroxymethylationDNA methylationgene expressionSprouty4

Identifiers

PMID36384366
PMCPMC9980603
OpenAlexW4309247810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.